![]() ![]() | Andre, S., Larbanoix, L., Verteneuil, S., Stanicki, D., Nonclercq, D., Vander Elst, L., Laurent, S., Muller, R., & Burtea, C. (05 June 2020). Development of an LDL receptor-targeted peptide susceptible to facilitate the brain access of diagnostic or therapeutic agents. Biology, 9, 161, 1-26. doi:10.3390/biology9070161 ![]() |
![]() ![]() | Burtea, C., Andre, S., & Laurent, S. (10 December 2019). Peptides binding to LDL receptor as carriers for crossing the blood-brain barrier. |
![]() ![]() | Andre, S., Atakana Lukulu, J. M., Lecomte, M., Muller, R., Vander Elst, L., Laurent, S., & Burtea, C. (28 October 2019). A promising phospholipase A2 targeted peptide slowing amyloid beta pathology in an Alzheimer's disease mouse model. Poster session presented at the 2nd International Conference on Neurovascular and Neurodegenerative Diseases, Paris, France. |
![]() ![]() | Andre, S., Atakana Lukulu, J. M., Lecomte, M., Muller, R., Vander Elst, L., Laurent, S., & Burtea, C. (24 May 2019). Development of an original phospholipase A2-targeted peptide able to reduce amyloid pathology in a mouse model of Alzheimer's disease. Poster session presented at 13th National Congress of the Belgian Society for Neuroscience, Brussels, Belgium. doi:10.3389/conf.fnins.2019.96.00032 |
![]() ![]() | TCHEOUBI, S. E. R., Andre, S., Laurent, S., & Burtea, C. (18 March 2019). Nouvelle Approche de Ciblage Moléculaire dans le Domaine de la Santé. Poster session presented at Evénement de maillage UMONS-CHU Ambroise Paré (UMHAP), Mons, Belgium. |
Andre, S., Lecomte, M., Muller, R., Vander Elst, L., Laurent, S., & Burtea, C. (07 July 2018). Phospholipase A2 targeting for the development of an original therapeutic strategy in the context of Alzheimer's disease. Paper presented at 11th FENS Forum of Neuroscience, Berlin, Germany. |
Andre, S., Lecomte, M., Muller, R., Vander Elst, L., Laurent, S., & Burtea, C. (28 February 2018). Therapy of Alzheimer's disease: inhibitory potential of a phospholipase A2-targeted peptide able to cross the blood-brain barrier. Poster session presented at Belgian peptide Group Meeting, Bruxelles, Belgium. |
![]() ![]() | Andre, S., Ansciaux, E., Saidi, E., Larbanoix, L., Stanicki, D., Nonclercq, D., Vander Elst, L., Laurent, S., Muller, R., & Burtea, C. (07 November 2017). Validation by magnetic resonance imaging of the diagnostic potential of a heptapeptide-functionalized imaging probe targeted to amyloid beta and able to cross the blood-brain barrier. Journal of Alzheimer's Disease, 60 (4), 1547-1565. doi:10.3233/JAD-170563 ![]() |
Andre, S., Daldal, F., Lecomte, M., Muller, R., Vander Elst, L., Laurent, S., & Burtea, C. (22 May 2017). The phospholipase A2 signaling as a new therapeutic biomarker of Alzheimer's disease: modulation through phage display-derived peptides able to cross the blood-brain barrier. Poster session presented at 12th Meeting of the Belgian Neutoscience Society, Ghent, Belgium. doi:10.3389/conf.fnins.2017.94.00057 |
Andre, S., Daldal, F., Delcroix, M., Verteneuil, S., Muller, R., Vander Elst, L., Laurent, S., & Burtea, C. (16 May 2017). Blood-brain barrier crossing for improving brain access using a peptide able to bind a receptor-mediated transcytosis. Paper presented at BMIC, Bruxelles, Belgium. |
Andre, S., Daldal, F., Delcroix, M., Muller, R., Vander Elst, L., Laurent, S., & Burtea, C. (10 April 2017). Towards the therapy of Alzheimer's disease via the inhibition of a phospholipase A2 isoform using peptides able to cross the blood-brain barrier. Poster session presented at BNA 2017 : festival of neuroscience, Birmingham, United Kingdom. |
Andre, S., Daldal, F., Delcroix, M., Muller, R., Vander Elst, L., Laurent, S., & Burtea, C. (07 March 2017). Targeting phospholipase A2 for the treatment of Alzheimer's disease through a peptidic modulation. Poster session presented at MDC : Mardi des Chercheurs 2017, Mons, Belgium. |
Andre, S., Daldal, F., Delcroix, M., Muller, R., Vander Elst, L., Laurent, S., & Burtea, C. (10 December 2016). Phospholipase A2 modulation in Alzheimer's disease: new approach of treatment using peptides able to accede to the brain through the LDL receptor. Poster session presented at Joint meeting of the Belgian Neurological Society and Belgian Dementia Council (BeDeCo) December 10th 2016, Antwerp, University of Antwerp, Belgium. |
Andre, S., Ansciaux, E., Larbanoix, L., Fanfone, D., Nonclercq, D., Vander Elst, L., Laurent, S., Muller, R., & Burtea, C. (29 November 2016). Targeting amyloid plaques for the early diagnosis of Alzheimer's disease: validation of a vectorized superparamagnetic contrast agent able to cross the blood-brain barrier. Poster session presented at BMIC 'Imaging in Drug Discovery and development', Janssen Pharmaceutica, Beerse, Belgium. |
Andre, S., Daldal, F., Delcroix, M., Muller, R., Vander Elst, L., Laurent, S., & Burtea, C. (08 October 2016). New therapeutic management of Alzheimer's disease: interest to a phospholipase A2-targeted peptide able to cross the blood-brain barrier through the LDL receptor. Poster session presented at Belgian Brain Congress, MICX. October 8, 2016, Mons, Belgium. doi:10.3389/conf.fnagi.2016.03.00046 |
Andre, S., Verteneuil, S., Delcroix, M., Muller, R., Vander Elst, L., Laurent, S., & Burtea, C. (08 June 2016). Stratégie thérapeutique de la maladie d'Alzheimer par délivrance ciblée et modulation peptidique d'une phospholipase. Poster session presented at 13ème RFMASA Réunion francophone sur la maladie d'Alzheimer et les syndromes apparentés. 8 au 10 juin 2016, Lyon, France. |
Andre, S., Daldal, F., Delcroix, M., Muller, R., Vander Elst, L., Laurent, S., & Burtea, C. (18 May 2016). Approche thérapeutique de la maladie d'Alzheimer : passage de la barrière hémato-encéphalique et modulation peptidique d'une phospholipase A2. Poster session presented at 9ème édition de la Matinée des Chercheurs 2016 (MdC2016); Mons; Belgique; 2015, Valenciennes, France. |
Andre, S., Verteneuil, S., Delcroix, M., Muller, R., Vander Elst, L., Laurent, S., & Burtea, C. (17 February 2016). Peptide-mediated modulation of a phospholipase isoform and blood-brain barrier transcytosis in the context of Alzheimer's disease therapy. Poster session presented at Belgian Peptide Group Meeting, Bruxelles, Belgium. |
Andre, S., Verteneuil, S., Delcroix, M., Muller, R., Vander Elst, L., Laurent, S., & Burtea, C. (22 May 2015). Development of a new therapeutic approach for Alzheimer's disease by phospholipase pathway modulation and blood-brain barrier shuttling. Paper presented at 11th National Congress of the Belgian Society for Neuroscience, Mons, Belgium. doi:10.3389/conf.fnins.2015.89.00068 |
Andre, S., Verteneuil, S., Muller, R., Vander Elst, L., Laurent, S., & Burtea, C. (10 March 2015). Toward the development of a therapeutic strategy applied to Alzheimer's disease via phospholipase signaling. Poster session presented at 8ème édition de la Matinée des Chercheurs 2015 (MdC2015), Mons, Belgium. |